Skip to content

The Role of Zamzam Water in Idiopathic Oligohydramnios

Effect of Zamzam Water on Amniotic Fluid Index, in Oligohydramnios : a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04684680
Enrollment
120
Registered
2020-12-24
Start date
2021-01-01
Completion date
2021-11-01
Last updated
2021-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oligohydramnios

Brief summary

The aim of this study is to evaluate the efficacy of drinking zamzam water versus tap water in increasing the AF index in women with oligohydramnios.

Detailed description

Oligohydramnios refers to decrease in amniotic fluid and it is defined as a deepest fluid pocket of less than 2 cm or an amniotic fluid index of 5 cm or less. Oligohydramnios complicates 0.5% to 8% of pregnancies, and 12 % if postdates When it occurs in first half of pregnancy it is associated with birth defects while in second half it causes poor fetal growth, malpresentations , FHR decelerations , MAS , Fetal suicidal syndrome and increases cesarean section and management and prognosis depend on gestational age

Interventions

DIETARY_SUPPLEMENTzamzam water

will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term

DIETARY_SUPPLEMENTtap water

will receive the normal need of daily requirement of water (2.5 liter) in form of tap water

Sponsors

Aswan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

open label randomized controlled trial

Intervention model description

open label randomized controlled trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* pregnant female with idiopathic oligohydramnios

Exclusion criteria

* patients with medical disorder * congenital anomalies * premature rupture of membrane * Patient refuse to participate

Design outcomes

Primary

MeasureTime frameDescription
amniotic fluid index10 weeksthe change of the amniotic fluid volume

Countries

Egypt

Contacts

Primary ContactHany f Sallam, md
hanygyne@yahoo.com+201022336052
Backup Contactnahla w shady, md
nahlagyn@yahoo.com+201022336052

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026